Drugs / SHR-3045
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07200596 | Oct 2025 → Mar 2026 | rheumatoid arthritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06883695 | Apr → Jun 2025 | rheumatoid arthritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07233655 | Jan → Apr 2026 overdue | rheumatoid arthritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-3045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07233655 ↗ |
| Route | Subcutaneous | “single-dose subcutaneous injection of SHR-3045” NCT07200596 ↗ |